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1. Introduction 2. Materials and methods 
The similarity between the mode of action of pro- 
teolytic enzymes and ribosomal peptidyltransferase- 
catalyzed peptide bond formation isof considerable 
current interest [1,2]. Peptidyltransferase canfunc- 
tion essentially in three possible ways: 
(i) Via a double displacement mechanism involving 
an acyl-enzyme (ribosome) intermediate asfound 
in serine proteases [3 ]; 
(ii) By a direct ransfer of peptidyl residue to amino- 
acyl function without forming a covalent ribo- 
somal intermediate orcatalytic participation of 
the ribosome [4]; or 
('tii) Via a concerted cyclic mechanism which includes 
both transfer of peptidyl moiety and proton [5] 
from a suitably oriented functional group on the 
ribosome. 
One approach to an evaluation of possibility (i) is to 
study a response of some known inhibitors of proteo- 
lytic enzymes in a suitable model system of peptidyl- 
transferase-catalyzed peptide bond formation. Thus, 
it was reported [6] that phenylboronic a ids, a group 
of chymotrypsin irthibitors [7], inhibited the fragment 
reaction and also, to a lesser extent, the reaction of 
N-Ac-Phe-tRNA with puromycin. Unlike proteases, 
which are fairly specific for distinct amino acids, ribo- 
somal peptidyltransferase is capable of catalyzing 
peptide-bond formation with aminoacyl tRNAs derived 
from all 20 amino acids. It is then likely that peptidyl- 
transferase can incorporate the active site features of 
proteolytic enzymes other than simply those of 
chymotrypsin. Therefore, it was of interest to study a 
group of aromatic amidines, which are known to 
inhibit trypsin [8] as possible inhibitors of peptidyl- 
transferase. 
All amidine derivatives, L-arginine and sodium 
benzoate, used here, were commercial products of the 
highest available purity./3-Phenylethylboronic acid 
was prepared as in [9,10]. The pH of all inhibitor solu- 
tions was adjusted to 7.4 with HC1 or NaOH prior to 
the assay. Inhibition of the puromycin reaction was 
performed as in [11 ]. A typical reaction mixture con- 
rained in 0.1 ml: 0.05 M Tris-HC1 (pH 7.4), 0.1 M 
NH4CI, 0.01 M MgC12, 4.0 A26o units of NH4-washed 
70 S ribosomes from E. coli MRE 600 cells, 10 g 
poly(U), 0.20 A26o units of N-Ac-[14C]Phe-tRNA 
(~5200 cpm, spec. act. 0.84 nmol [~4C]phenylala- 
nine/mg tRNA), puromycin 1X 10 -s M and inhibitor 
at desired concentrations. Following the incubation 
at 37°C for 30 mill, the reaction was stopped by addi- 
tion of 0.1 ml 0.1 M Be(NOa)2 in 0.3 M acetate buffer 
(pH 5.5) saturated with MgSO4 and the products were 
extracted with 1.5 ml ethyl acetate. Ethyl acetate 
phase (1 ml) was transferred to a scintillation vial and 
the radioactivity was determined in 10 ml Scinti 
Verse TM scintillation mixture (Fisher Scientific Co., 
Fair Lawn N J) in a Packard Tri-Carb liquid scintilla- 
tion spectrometer at 73% counting efficiency. Percent 
inhibition represents he difference in ethyl acetate 
extracted N-acetyl-L- [ ~4 C] phenylalanylpuromycin 
counts in the absence and in the presence of inhib- 
itors. Further experimental details are provided in the 
figure legends. 
3. Results and discussion 
The results of inhibition of the puromycin reaction 
with benzamidine and some related compounds are 
summarized in fig. 1. It is clear that carboxamidine 
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Fig.1. The inhibition of peptidyltransferase-catalyzed N-Ac-
Phe-puromycin formation by amidine derivatives and sodium 
benzoate. For assay conditions ee section 2: m-nitrobenzam- 
idine • HC1 (e); p-aminobenzamidine - 2 HCI (z~); benzami- 
dine • HCI (A);N-phenylguanidine carbonate (n); L-arginine 
(v); sodium benzoate (o); and acetamidine - HCI (v). 
derivatives containing an aromatic (phenyl) group were 
the most potent inhibitors. Thus, m-nitrobenzamidine 
appears as the most active compound followed closely 
by p-aminobenzamidine and benzamidine itself. 
N-Phenylguanidine was the weakest inhibitor of the 
investigated aromatic derivatives containing a carbox- 
amidine group. Removal of the phenyl group led to a 
substantial decrease of the inhibitory activity. Thus, 
both arginine and acetamidine did not inhibit puromy- 
cin reaction at <10 -:  M. This agrees with [12] where 
arginine inhibited the fragment reaction between 
C(U) -A -C-C-A- (AcLeu)  and puromycin at 
~10 -2 M, but was without effect on the puromycin 
reaction with intact N-Ac-Phe-tRNA. Finally, the 
importance of carboxamidine moiety, apart from the 
effect of the aromatic portion, follows from an exper- 
iment with sodium benzoate. The latter anion, which 
is stericaUy similar to benzamidine but has an opposite 
charge, was virtually devoid of activity. 
A comparison of the inhibitory potency of aro- 
matic amidines toward peptidyltransferase and trypsin 
is of additional interest (table 1). Although the inhibi- 
tion is lower in peptidyltransferase-catalyzed than in 
trypsin-catalyzed reaction, the pattern is strikingly 
similar. The small differences between p-amino- and 
m-nitrobenzamidine and the fact that the m-nitro 
derivative is more inhibitory than the p-amino com- 
pound is difficult to reconcile with electronic effects 
of the respective substituents. The m-nitro derivative 
Table 1 
Inhibition of trypsin and peptidyltransferase-catalyzed 
reactions with amidine derivatives 
Compound K i (M X lO s) IDso X 10 3 
(trypsin) a (peptidyltransferase) 
Benzamidine 1.84 8.0 b 
p-Aminobenzamidine 0.825 5.8 
m-Nitrobenzamidine - 4.3 
N-Phenylguanidine 7.25 12.0 
Acetamidine 3.650 c 
a Values taken from [8] 
b Ki = 5.5 X 10 -3 M, as determined from Lineweaver-Burk 
plot (fig.2) 
c About 20% inhibition of 0.1 M 
was the strongest inhibitor of the fragment reaction 
among the group of phenylboronic acids studied in 
[6]. This observation was attributed to the corre- 
sponding substituent effect which had also been 
invoked in the case of chymotrypsin [7]. However, 
the same explanation is insufficient o account for 
the observed high inhibitory activity of m-nitrobenz- 
amidine because lectronic effects would lead to a 
decrease in the basicity of the carboxamidine group 
and, presumably, the extent of inhibition. Therefore, 
such influences as the positioning of the inhibitor 
between groups of the opposite charge in the binding 
site, which could offset the adverse influence on the 
basicity (formula 1), should be considered. Comparison 
of the inhibitory potency of both groups of inhibitors 
is also of interest. Thus, phenylboronic acid at 
1 X 10 -2 M caused ~30% inhibition [6] of the puro- 
mycin reaction with N-Ac-Phe-tRNA whereas the 
same level of inhibition with benzamidine was reached 
at ~5 X 10 .3 M (fig.l). Therefore, the extent of inhi- 
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Experiment with 13-phenylethylboronic acid (I), a 
strong inhibitor of chymotrypsin [ 13], has indicated 
that differences between the interaction of boronic 
acid derivatives with chymotrypsin and peptidyltrans- 
ferase may be more substantial than simply the degree 
of inhibition. Thus, compound I was non-inhibitory 
up to 2.6 X 10 -3 M despite the fact that the K i values 
of chymotrypsin hibition with phenylboronic [7] 
and/3-phenylethylboronic acid [13] are 2 × 10 -4 and 
4 × 10 -s M, respectively. Interesting differences were 
also found in the enzyme kinetics of phenylboronic 
acids and benzamidines in the peptidyltransferase- 
catalyzed reactions. Thus, the former are competitive 
inhibitors [6] of puromycin, acting at the A-site of 
peptidyltransferase, in contrast o benzamidine which 
is a non-competitive inhibitor (fig.2,3). Consequently, 
benzamidine must act at a locus different from the 
A-site. It should be emphasized that benzamidine is a 
competitive inhibitor of trypsin [8] that is located 
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Fig.2. Lineweaver-Burk plot of the effect of benzami- 
dine • HC1 on the rate of N-Ac-Phe-puromycin formation. 
The initial velocity was determined as the amount of radio- 
activity extracted in 1 ml ethyl acetate in the first 5 min of 
reaction at 32°C. For experimental conditions ee section 2. 
Inset shows the linear relationship between the concentration 
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Fig.3. Dixon plot of the effect of benzamidine • HC1 on the 
rate of N-Ac-Phe-puromycin formation. For conditions ee 
fig.2 and section 2. 
between the anionic and hydrophobic portion of the 
enzyme active site [14]. A similar interaction of 
benzamidine can then take place with the requisite 
portion of the ribosome, presumably the P-site. It is 
even possible that the A-site of peptidyltransferase 
resembles more closely chymotrypsin than trypsin 
whereas the opposite is true for the P-site. 
Comparison of benzamidine with a somewhat 
structurally similar derivative, arginine, is also of inter- 
est. The latter, which is apparently a weaker inhibitor 
than benzamidine, inhibited the fragment reaction 
[ 12] competitively with 2 molecules bound to the 
A-site of peptidyltransferase. However, only one mol- 
ecule of non-competitive inhibitor benzamidine is
involved in binding, as shown by linearity of  the slope 
vs  inhibitor concentration plot (fig.2, inset). 
A generally weaker esponse of peptidyltransferase- 
catalyzed peptide bond formation toward low-M r 
inhibitors, such as phenylboronic acids [6] or benzam- 
idines relative to that of chymotrypsin- [7] or trypsin- 
catalyzed [8] reactions, is probably the consequence 
of a complexity of the ribosome and hence stricter 
217 
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structural requirements for inhibition. A high afffmity 
of N-Ac-Phe-tRNA toward the P-site could also affect 
the magnitude of inhibition. 
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